NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update

Core Insights - NeuroSense Therapeutics reported significant advancements in its lead drug candidate PrimeC, transitioning from a Phase 2b program to a late-stage clinical asset with a clear regulatory path [2][3] - The company demonstrated a 33% slowing in disease progression in ALS patients over 18 months and achieved a 65% reduction in the risk of death with a median survival benefit of over 14 months [2][4][6] - PrimeC's results were published in JAMA Neurology, validating its clinical and biological activity [5][6] Business Highlights from 2025 - NeuroSense advanced PrimeC into a late-stage clinical asset with FDA clearance for the PARAGON Phase 3 trial in ALS [3][6] - The Phase 2b PARADIGM study showed a significant reduction in ALS-related complications and supported PrimeC's potential as a disease-modifying therapy [2][3] - The company completed commercial-scale manufacturing and engaged with Health Canada for regulatory strategy [3] Recent Developments and First Quarter 2026 Highlights - In 2026, NeuroSense reported statistically significant survival data from its Phase 2b study, reinforcing PrimeC's clinical package [4][5] - The company expanded its scientific visibility through presentations at international conferences and strengthened its intellectual property portfolio with new patents [5][6] Financial Results - Research and development expenses for 2025 were $6.2 million, an increase of 8.8% from 2024, primarily due to higher share-based payment expenses [7] - General and administrative expenses rose to $4.9 million, a 16.6% increase from the previous year, also driven by share-based compensation [8] - As of December 31, 2025, NeuroSense had cash of approximately $0.2 million, down from $3.4 million in 2024 [8][10] Consolidated Financial Position - Total assets as of December 31, 2025, were $1.028 billion, a decrease from $4.575 billion in 2024 [10][13] - Total liabilities increased to $2.588 billion from $1.992 billion in 2024, indicating a growing financial burden [12][13] - The company reported a net loss of $11.125 million for 2025, compared to a loss of $10.210 million in 2024 [13][14]